SNOA vs. CYTO, QNRX, GMDA, EIGR, ELOX, CYCC, CWBR, DYNT, TNON, and ONCO
Should you be buying Sonoma Pharmaceuticals stock or one of its competitors? The main competitors of Sonoma Pharmaceuticals include Altamira Therapeutics (CYTO), Quoin Pharmaceuticals (QNRX), Gamida Cell (GMDA), Eiger BioPharmaceuticals (EIGR), Eloxx Pharmaceuticals (ELOX), Cyclacel Pharmaceuticals (CYCC), CohBar (CWBR), Dynatronics (DYNT), Tenon Medical (TNON), and Onconetix (ONCO). These companies are all part of the "medical" sector.
Altamira Therapeutics (NASDAQ:CYTO) and Sonoma Pharmaceuticals (NASDAQ:SNOA) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, valuation, dividends, media sentiment, institutional ownership, community ranking, profitability, earnings and risk.
Altamira Therapeutics has a beta of 1.79, indicating that its share price is 79% more volatile than the S&P 500. Comparatively, Sonoma Pharmaceuticals has a beta of 1.28, indicating that its share price is 28% more volatile than the S&P 500.
1.9% of Altamira Therapeutics shares are owned by institutional investors. Comparatively, 2.0% of Sonoma Pharmaceuticals shares are owned by institutional investors. 13.0% of Altamira Therapeutics shares are owned by insiders. Comparatively, 9.2% of Sonoma Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
In the previous week, Altamira Therapeutics had 2 more articles in the media than Sonoma Pharmaceuticals. MarketBeat recorded 3 mentions for Altamira Therapeutics and 1 mentions for Sonoma Pharmaceuticals. Sonoma Pharmaceuticals' average media sentiment score of 0.70 beat Altamira Therapeutics' score of -1.00 indicating that Altamira Therapeutics is being referred to more favorably in the media.
Sonoma Pharmaceuticals received 216 more outperform votes than Altamira Therapeutics when rated by MarketBeat users.
Altamira Therapeutics has a net margin of 0.00% compared to Altamira Therapeutics' net margin of -41.24%. Sonoma Pharmaceuticals' return on equity of 0.00% beat Altamira Therapeutics' return on equity.
Sonoma Pharmaceuticals has a consensus target price of $3.25, suggesting a potential upside of 1,944.03%. Given Altamira Therapeutics' higher probable upside, analysts plainly believe Sonoma Pharmaceuticals is more favorable than Altamira Therapeutics.
Altamira Therapeutics has higher earnings, but lower revenue than Sonoma Pharmaceuticals.
Summary
Altamira Therapeutics beats Sonoma Pharmaceuticals on 9 of the 14 factors compared between the two stocks.
Get Sonoma Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for SNOA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding SNOA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Sonoma Pharmaceuticals Competitors List
Related Companies and Tools
